Strongbridge Biopharma plc Announces Termination of Public Offering of Ordinary Shares
16 August 2018 - 9:12AM
Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today
announced that it has terminated the public offering of ordinary
shares previously announced on August 14, 2018. The
termination results from an assessment by the Company’s management
that current market conditions are not conducive for an offering on
terms that would be in the best interests of the Company’s
shareholders.
About Strongbridge Biopharma
plc
Strongbridge Biopharma is a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs. Strongbridge's rare endocrine
franchise includes MACRILEN™ (macimorelin), the first and only
FDA-approved oral drug indicated for the diagnosis of adult growth
hormone deficiency, RECORLEV™ (levoketoconazole), a cortisol
synthesis inhibitor currently being studied in Phase 3 clinical
studies for the treatment of endogenous Cushing's syndrome, and
veldoreotide extended release, a pre-clinical next-generation
somatostatin analog being investigated for the treatment of
acromegaly and potential additional applications in other
conditions amenable to somatostatin receptor activation. MACRILEN
has orphan drug exclusivity in the United States, and both RECORLEV
and veldoreotide have received orphan drug designation from the FDA
and the European Medicines Agency. The Company’s rare neuromuscular
franchise includes KEVEYIS® (dichlorphenamide), the first and only
FDA-approved treatment for hyperkalemic, hypokalemic, and related
variants of primary periodic paralysis. KEVEYIS has orphan drug
exclusivity in the United States.
Contacts:
Corporate and Media
RelationsElixir Health Public RelationsLindsay Rocco+1
862-596-1304lrocco@elixirhealthpr.com
Investor
RelationsUS:The Trout GroupMarcy Nanus+1
646-378-2927mnanus@troutgroup.com
Europe:First HouseGeir Arne
Drangeid +47 913 10 458strongbridgebio@firsthouse.no
USA:900 Northbrook DriveSuite
200Trevose, PA 19053Tel. +1 610-254-9200Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Strongbridge Biopharma PLC (NASDAQ): 0 recent articles
More News Articles